RiverPark Advisors LLC Has $2.26 Million Stake in Intuitive Surgical, Inc. (NASDAQ:ISRG)

RiverPark Advisors LLC decreased its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 17.3% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,666 shares of the medical equipment provider’s stock after selling 1,188 shares during the quarter. Intuitive Surgical makes up approximately 1.9% of RiverPark Advisors LLC’s portfolio, making the stock its 17th biggest position. RiverPark Advisors LLC’s holdings in Intuitive Surgical were worth $2,261,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the company. Central Pacific Bank Trust Division acquired a new stake in shares of Intuitive Surgical during the 1st quarter valued at $2,695,000. Whittier Trust Co. of Nevada Inc. lifted its holdings in Intuitive Surgical by 6.1% during the 1st quarter. Whittier Trust Co. of Nevada Inc. now owns 8,868 shares of the medical equipment provider’s stock worth $3,539,000 after buying an additional 509 shares during the period. Patron Partners LLC lifted its holdings in Intuitive Surgical by 3.9% during the 1st quarter. Patron Partners LLC now owns 1,776 shares of the medical equipment provider’s stock worth $709,000 after buying an additional 67 shares during the period. Whittier Trust Co. lifted its holdings in Intuitive Surgical by 2.6% during the 1st quarter. Whittier Trust Co. now owns 9,166 shares of the medical equipment provider’s stock worth $3,658,000 after buying an additional 229 shares during the period. Finally, Diversified LLC lifted its holdings in Intuitive Surgical by 6.4% during the 1st quarter. Diversified LLC now owns 695 shares of the medical equipment provider’s stock worth $277,000 after buying an additional 42 shares during the period. Institutional investors and hedge funds own 83.64% of the company’s stock.

Insiders Place Their Bets

In other Intuitive Surgical news, SVP Mark Brosius sold 175 shares of the business’s stock in a transaction that occurred on Monday, May 13th. The stock was sold at an average price of $389.16, for a total transaction of $68,103.00. Following the completion of the sale, the senior vice president now directly owns 883 shares of the company’s stock, valued at approximately $343,628.28. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, SVP Mark Brosius sold 175 shares of the business’s stock in a transaction that occurred on Monday, May 13th. The stock was sold at an average price of $389.16, for a total value of $68,103.00. Following the transaction, the senior vice president now owns 883 shares in the company, valued at approximately $343,628.28. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Craig H. Barratt sold 1,400 shares of the business’s stock in a transaction that occurred on Wednesday, June 12th. The stock was sold at an average price of $421.06, for a total value of $589,484.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 17,956 shares of company stock valued at $6,927,011. Corporate insiders own 0.80% of the company’s stock.

Analyst Ratings Changes

ISRG has been the topic of several recent research reports. Robert W. Baird cut their target price on Intuitive Surgical from $440.00 to $436.00 and set an “outperform” rating on the stock in a report on Friday, April 19th. BTIG Research lifted their target price on Intuitive Surgical from $412.00 to $421.00 and gave the stock a “buy” rating in a report on Friday, April 19th. Jefferies Financial Group lifted their target price on Intuitive Surgical from $365.00 to $375.00 and gave the stock a “hold” rating in a report on Friday, April 19th. Evercore ISI lifted their price objective on Intuitive Surgical from $385.00 to $425.00 and gave the stock an “in-line” rating in a research report on Tuesday, July 2nd. Finally, The Goldman Sachs Group started coverage on Intuitive Surgical in a research report on Thursday, May 30th. They issued a “buy” rating and a $500.00 price objective for the company. Six investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $407.68.

Intuitive Surgical Trading Down 0.5 %

Intuitive Surgical stock traded down $2.23 during midday trading on Tuesday, reaching $442.30. The stock had a trading volume of 886,435 shares, compared to its average volume of 1,509,367. The company has a fifty day moving average price of $413.05 and a two-hundred day moving average price of $388.89. The company has a market capitalization of $156.88 billion, a P/E ratio of 79.84, a PEG ratio of 5.73 and a beta of 1.39. Intuitive Surgical, Inc. has a 12 month low of $254.85 and a 12 month high of $448.10.

Intuitive Surgical (NASDAQ:ISRG) last issued its quarterly earnings data on Thursday, April 18th. The medical equipment provider reported $1.50 EPS for the quarter, topping analysts’ consensus estimates of $1.40 by $0.10. The firm had revenue of $1.89 billion during the quarter, compared to analyst estimates of $1.87 billion. Intuitive Surgical had a return on equity of 12.91% and a net margin of 27.16%. The company’s revenue for the quarter was up 11.5% on a year-over-year basis. During the same period in the previous year, the company posted $1.00 EPS. On average, equities research analysts predict that Intuitive Surgical, Inc. will post 4.8 earnings per share for the current fiscal year.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.